Bayer’s NUBEQA combo shows 71% drop in risk of progression or death in prostate cancer trial

Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm

FDA grants accelerated approval to BEQALZI for relapsed mantle cell lymphoma

Lupin debuts in Dow Jones best-in-class indices for ESG performance

The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index

Medix Biochemica unleashes $5 million expansion to secure future of IVD supply chain

The global diagnostics supplier said the multi-phase expansion aims to deliver more than 60 commercially available recombinant antigen products by 2030

Precision oncology must be decentralized to reach every patient: Dr Vidya Veldore, Vice President, Clinical Operations, 4baseCare

Access to genomic testing, not therapy cost, is the biggest challenge

Glenmark Pharma introduces Vancomycin Injection in U.S. market

The product is bioequivalent and therapeutically equivalent to the reference listed drug by Fresenius Kabi USA, LLC.

Kotak Alts invests Rs. 200 million in Cellogen Therapeutics

Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities

Alembic Pharmaceuticals posts strong Q4 FY26 growth as net profit jumps 29%

US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya

Akums Q4 revenue climbs to Rs. 1,158 crore; PAT surges 135%

FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies

Mankind launches ‘Act at 30’ campaign to push early heart health screening

Nationwide preventive health initiative aims to make cardiovascular screening at age 30 a standard healthcare milestone